Mendelian Randomization review links Lp(a) to inflammatory protein pathways
This is a Mendelian Randomization analysis, not a primary clinical trial. The scope was to use genetic instruments for Lp(a) blood concentrations to identify associated proteins and pathways relevant to major adverse cardiovascular events (MACE).
The authors identified a total of 521 proteins associated with Lp(a). Pathway enrichment analysis then highlighted 91 Lp(a) downstream proteins comprising MACE-relevant pathways. These pathways include oxidized phospholipid-related processes, chemotaxis of immune cells, endothelial cell activation, pro-inflammatory monocyte activation, neutrophil activity, coagulation, and lipid metabolism.
The analysis is observational in nature, using genetic proxies to infer associations. The authors note that the results suggest the influence of Lp(a) may be primarily through modifying inflammation rather than lipid-lowering, providing a mechanistic framework. However, the study does not report effect sizes, p-values, confidence intervals, or a specific study population.
Limitations include the inferential nature of Mendelian Randomization and the lack of reported statistical measures for the protein associations. Practice relevance is restrained; the findings offer insight into potential biological mechanisms but do not provide direct evidence for clinical interventions or trial outcomes.